SCHEMBL3480696

SCHEMBL3480696

O=C(NCc1ccc(S(=O)(=O)N2CCC(NCc3ccc(C(F)C(F)F)cc3)CC2)s1)c1ccc(Cl)cc1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPK9 P45984 1/20 0.54
MAPK10 P53779 1/20 0.54
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
ALDH1A1 P00352 5/20 0.43
POLB P06746 2/20 0.43
LMNA P02545 1/20 0.42
TGM2 P21980 2/20 0.41
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
SMYD3 Q9H7B4 1/20 0.40
NAMPT P43490 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
EPHX2 P34913 1/20 0.39
USP5 P45974 1/20 0.39
SLC13A5 Q86YT5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3480030 0.88 MAPK9 (0.53) MAPK9MAPK10MEN1KMT2AALDH1A1
SCHEMBL3480150 0.88 MAPK9 (0.56) MAPK9MAPK10MEN1KMT2AALDH1A1
SCHEMBL3480372 0.86 MAPK9 (0.56) MAPK9MAPK10MEN1KMT2AALDH1A1
SCHEMBL3480147 0.86 MAPK9 (0.56) MAPK9MAPK10MEN1KMT2AALDH1A1
SCHEMBL3480239 0.85 MAPK9 (0.54) MAPK9MAPK10MEN1KMT2AALDH1A1
SCHEMBL3480444 0.85 MAPK9 (0.53) MAPK9MAPK10MEN1KMT2AALDH1A1
SCHEMBL3480193 0.85 MAPK9 (0.53) MAPK9MAPK10MEN1KMT2AALDH1A1
SCHEMBL3479939 0.84 MAPK9 (0.56) MAPK9MAPK10MEN1KMT2AALDH1A1
SCHEMBL3479860 0.84 MAPK9 (0.58) MAPK9MAPK10MEN1KMT2AALDH1A1
SCHEMBL3479807 0.83 MAPK9 (0.59) MAPK9MAPK10MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705052-B2 Sulfonamide derivatives for the treatment of diabetes MERCK SERONO SA (CH) 2010-04-27 US disclosed
US-20070043027-A1 Sulfonamide derivatives for the treatment of diabetes APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043027-A1 Sulfonamide derivatives for the treatment of diabetes CBR3, INSR, CS MAPK9 2768/4885MAPK10 1940/4885MEN1 3205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.